News and Events

The HIV care landscape is constantly evolving, with breakthroughs in the methods, strategies and treatments to control and prevent transmission. This section aims to provide timely news updates and clinically relevant information about HIV disease management to clinicians who are actively involved in HIV care.

Upcoming events such as conferences, online seminars and continuing education programs will be listed here on a regular basis.

2nd October 2018

Guideline recommendations

Key recommendations from the latest EACS and DHHS guidelines for ODEFSEY®▼ (emtricitabine / rilpivirine / tenofovir alafenamide) are listed below, with links to the full publications.

2nd October 2018

Key facts

Please click on the tabs below to find recommendations on how to prescribe ODEFSEY®▼ (emtricitabine / rilpivirine / tenofovir alafenamide). Full details can be found in the ODEFSEY® Summary of Product Characteristics.

2nd October 2018

Safety and tolerability

The table below lists the most frequently reported adverse reactions with ODEFSEY®▼(emtricitabine / rilpivirine / tenofovir alafenamide) in clinical studies of treatment-naïve HIV-positive individuals.1†

2nd October 2018

Efficacy and resistance

The clinical evidence to support ODEFSEY®▼ (emtricitabine / rilpivirine / tenofovir alafenamide) for the treatment of adults with HIV infection is based on:

  • studies conducted with FTC/TAF when given with cobicistat-boosted elvitegravir (EVG/c) as a fixed-dose combination (GENVOYA®▼);1
  • studies of rilpivirine (RPV) when given with TRUVADA® (FTC/TDF) as individual components or as a fixed-dose combination EVIPLERA®,1 and
  • two phase 3, 96-week, randomised, double-blind, active-controlled studies among virologically suppressed adults switching from the TDF-based regimens EVIPLERA® or ATRIPLA®.2,3